Abstract:OBJECTIVE:To assess the efficacy of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes.METHODS:Clinical data of 48 patients diagnosed and treated for mTNBC between 2004 and 2012 at the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) were retrospectively analyzed. All patients were pretreated with anthracyclines and at least one taxane in neo-adjuvant, adjuvant or chemotherapy for mTNBC and patients should be having at least one measurable metastatic lesion. Totally, 48 patients were included in this study, of which 21 cases received first-line chemotherapy and 27 cases received second-line chemotherapy. Based on the regimen they received, 22 patients were treated with NVB plus platinum (NP), and 26 patients with NVB plus capecitabine (NX).RESULTS:After 70 months follow-up, in the total group of patients, the objective response rate was 20.8%, clinical benefit rate was 43.8%, median progression free survival (PFS) was 4.4 months and median overall survival (OS) was 15.5 months. In addition, the ORR was significantly better in the NP arm versus NX arm (33.8% vs.7.7%, P=0.029) as well as PFS was statistically improved in the NP arm than NX arm (5.3 m vs. 3.0 m, P=0.023). Similar trend was observed in the OS, although the difference was not statistically significant (27.7 m vs. 14.8 m, P=0.077). In all, the most frequently reported adverse events were G1/2 gastrointestinal toxicity (68.8%) and neutropenia (62.5%) . No significant difference was observed between the NP arm and NX arm (P>0.05). The percentage of patients who delayed chemotherapy administration in the NP arm and NX arm was 9.1% (n=2), and 3.8% (n=1), respectively.CONCLUSIONS:NVB-based combination chemotherapy demonstrates moderate efficacy in mTNBC patients pretreated with anthracyclines and one taxane with manageable toxicity. NP regimen shows potential superiority over NX regimen, and should be further verified in randomized phase III clinical trial in larger cohort.

Clinical observation of NVB-contained chemotherapeutic regimen in advanced breast cancer

Clinical Observation of Gemcitabine Combined with Cisplatin As Second- or Third-Line on Patients with Advanced Triple-Negative Breast Cancer

A Systematic Review of Vinorelbine for the Treatment of Breast Cancer.

Chemotherapy of NA and NP regimens in 48 patients with advanced breast cancer

Clinical Observation on Navelbine Combined with Pirarubicin in Treatment of Multiple Myeloma by Combined Chemotherapy

Evaluation of Efficacy and Toxicity of Gemcitabine in Combination with Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

[Efficacy and Toxicity of Vinorelbine (Nvb)-Based Regimens in Patients with Metastatic Triple Negative Breast Cancer (mtnbc) Pretreated with Anthracyclines and Taxanes].

Clinical Observation of Epirubicin-contained Chemotherapeutic Regimens in Non-small Cell Lung Cancer

A Clinical Study on the Safety of Vinorelbine Combined with Cisplatin in the Treatment of the Postoperative Adjuvant Chemotherapy in Breast Cancer

A Study of the Radiosensitizing Effect of Low-dose Navelbine in the Treatment of Locally Advanced Non-small Cell Cancer of the Lung

Experimental Study of Enhanced Cytotoxicity of Navelbine to Human Pulmonary Carcinoma Cells A549 with Hyperthermia

Clinical efficacy of navelbine plus cisplatin in the treatment of advanced non - small cell lung cancer

Clinical Observation of Lobaplatin Plus Vinorelbine in Treating 46 Advanced Breast Cancer Patients

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

Navelbine Combined with Cisplatin,leucovorin and 5-Fluorouracil for Advanced Esophageal Carcinoma

Clinical study of Lobaplatin combined with Navelbine for advanced non-small cell lung cancer

Comparison of NP Regimen and TP Regimen in Treatment of Advanced Breast Cancer

Vinorelbine based combination chemotherapy in advanced non-small cell lung cancer

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

A Randomized Comparative Trial of NVB Alone Versus NVB Plus DDP for Treatment of Elderly Patients with Non-Small Cell Lung Cancer

Clinical Observation on Concurrent Radiotherapy in Combination with Vinorelbine and Cisplatin for Advanced Non-small-cell Lung Cancer